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ECMMinocycline is an inhibitor of matrix metalloproteinases (MMPs) and has been shown to have analgesic effects.
Whilst increased expression of MMPs is associated with neuropathic pain, MMPs also play crucial roles in
Wallerian degeneration and nerve regeneration. In this study we examined the expression of MMP-2, MMP-9
and tissue inhibitor of metalloproteinase (TIMP)-1/-2 in the sciatic nerve of control and streptozotocin-
induced diabetic rats treated with either vehicle or minocycline by quantitative PCR and gelatin zymography.
We assessed the effects of minocycline on nerve conduction velocity and intraepidermal nerve ﬁbre (IENF)
deﬁcits in diabetic neuropathy and investigated the effects of minocycline or MMP-2 on neurite outgrowth
from primary cultures of dissociated adult rat sensory neurons.
We show that MMP-2 is expressed constitutively in the sciatic nerve in vivo and treatment with minocycline or
diabetes leads to downregulation of MMP-2 expression and activity. The functional consequence of this is IENF
deﬁcits in minocycline-treated nondiabetic rats and an unsupportive microenvironment for regeneration in
diabetes. Minocycline reduces levels of MMP-2 mRNA and nerve growth factor-induced neurite outgrowth.
Furthermore, in vivominocycline treatment reduces preconditioning-induced in vitro neurite outgrowth follow-
ing a sciatic nerve crush. In contrast, the addition of activeMMP-2 facilitates neurite outgrowth in the absence of
neurotrophic support and pre-treatment of diabetic sciatic nerve substrata with active MMP-2 promotes a
permissive environment for neurite outgrowth. In conclusion we suggest that MMP-2 downregulation may
contribute to the regenerative deﬁcits in diabetes. Minocycline treatment also downregulates MMP-2 activity
and is associated with inhibitory effects on sensory neurons. Thus, caution should be exhibited with its use as
the balance between beneﬁcial and detrimental outcomes may be critical in assessing the beneﬁts of using
minocycline to treat diabetic neuropathy.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Diabetic neuropathy (DPN) is a common secondary complication of
diabetes mellitus, which is associated with biochemical and structural
changes in the nervous system including nerve conduction velocity
(NCV) deﬁcits and altered mechanical and thermal sensitivity
(Tomlinson and Gardiner, 2008). A common feature of both clinical
and experimental diabetic neuropathy is degeneration of distal nerve ﬁ-
bres and a reduced capacity for regeneration of injured axons
(Beiswenger et al., 2008; Christianson et al., 2006; Kennedy and
Zochodne, 2000; Kennedy and Zochodne, 2005). This leads to numb-
ness, loss of protective sensation and an increased risk of amputation.
Other than glycaemic control there is no effective treatment and current
strategies which treat neuropathic pain do not encourage neuronal.J. Gardiner).
. This is an open access article underrepair (Tesfaye et al., 2013). There is therefore an unmet clinical need
for effective treatments for DPN targeting both nerve regeneration and
neuropathic pain.
Minocycline is a semi-synthetic analogue of tetracycline and awide-
ly prescribed generic drug used to treatmicrobial infections. It has been
shown to have anti-inﬂammatory, neuroprotective, anti-oxidative, and/
or analgesic effects in a number of disease models and this paired with
the good safety record of minocycline in patients has paved the way for
clinical studies in a number of neurodegenerative diseases (Plane et al.,
2010). The mechanisms underlying the neuroprotective effects of
minocycline are unclear since minocycline inhibits multiple targets
including matrix metalloproteinase (MMP)-2 and MMP-9. The upregu-
lation ofMMPs has been linked to the development andmaintenance of
neuropathic pain (Kawasaki et al., 2008). In experimental diabetic
neuropathy the analgesic potential of minocycline has been explored
(Bhatt and Veeranjaneyulu, 2010; Morgado et al., 2011), but none of
these studies have investigated the effects on regeneration.the CC BY license (http://creativecommons.org/licenses/by/3.0/).
655S. Ali et al. / Experimental Neurology 261 (2014) 654–665MMPs are a large family of zinc-dependent proteolytic enzymes,
best known for their role in tissue remodelling, degradation of extracel-
lular matrix (ECM) molecules, release of ECM-sequestered growth fac-
tors and cleavage and activation of membrane-bound cytokines and
their receptors (Sternlicht and Werb, 2001). Expression and activity of
MMPs are tightly regulated at three levels: by transcriptional regula-
tion; by activation — they are secreted in an enzymatically inactive
state as pro-enzymes which are activated in a proteolytic manner by di-
rect cleavage of the pro-peptide by another MMP or a non-proteolytic
manner by organomercurials; and by inhibition via interactions with
tissue inhibitors of MMPs (TIMPs) (Sternlicht and Werb, 2001).
In the peripheral nervous system the coordinated expression of
ECM,MMPs and TIMPs duringWallerian degeneration andnerve regen-
eration governs the success of nerve repair (Gantus et al., 2006). Follow-
ing nerve injury, there are spatial and temporal alterations in the
expression of MMPs. MMP-9 is rapidly and transiently upregulated at
sites of peripheral nerve injury (Demestre et al., 1999; Ferguson and
Muir, 2000; Shubayev and Myers, 2000) with increased expression in
Schwann cells, blood vessels, and activated macrophages. MMP-9 facil-
itates blood nerve barrier breakdown enablingmacrophage and neutro-
phil inﬁltration (Siebert et al., 2001) and is essential to Wallerian
degeneration (Hughes et al., 2002; Ide, 1996; Johnson et al., 2005;
Mantuano et al., 2008). MMP-2 mRNA and protein levels increase
later and remain upregulated up to 63 days post-nerve crush. Early
MMP-2 expression is in Schwann cells and endoneurial cells
(Demestre et al., 2004; La et al., 1996; Muir, 1994) whilst later MMP-2
is increased within the regenerating axons and degrades inhibitory
ECM components promoting a permissive environment for regenera-
tion (Ferguson and Muir, 2000; Zuo et al., 1998). MMP-2 knockout
mice show reduced regeneration of axons following spinal contusion in-
jury and impaired functional recovery (Hsu et al., 2006) highlighting the
importance of MMPs for successful regeneration.
A number of studies have described an increase in systemicMMPs in
diabetes (Jacqueminet et al., 2006) and altered expression of MMPs has
been implicated in the pathophysiology of a number of secondary com-
plications including nephropathy (Thrailkill et al., 2009) and poor
wound healing (Liu et al., 2009). To date, there is little information
about the expression or activity of MMPs and/or their role in the regen-
erative deﬁcits associated with diabetic neuropathy. The aims of this
study were (1) to compare the expression of MMP-2, MMP-9 and
TIMP-1/2 in the peripheral nerve of control rats and rats with
streptozotocin (STZ)-induced diabetes; (2) to assess the effects of
minocycline on indices of experimental diabetic neuropathy and regu-
lation of MMPs in the peripheral nerve; and (3) to investigate the effect
of MMP-2 and minocycline on in vitro sensory neuron growth.Table 1
Diabetic rats are signiﬁcantly lighter and hyperglycaemic compared to age-matched nondiabet
cose levels of control or diabetic rats (note, 1/10 rats from the diabetic-vehicle group and 5/10 r
post-STZ— their datawas excluded fromall analysis). For blood glucose levels greater than theu
mean ± s.d. ***p b 0.001 t-test and two-way ANOVA followed by Bonferroni posthoc tests.
Duration (weeks) Animal group (n numbers) Start body we
Timecourse study
4 Age-matched control (10) 340 ± 9
Diabetic (12) 339 ± 7
8 Age-matched control (10) 335 ± 5
Diabetic (12) 343 ± 3
12 Age-matched control (10) 334 ± 6
Diabetic (12) 342 ± 5
Minocycline study:
8 Nondiabetic-vehicle (8) 358 ± 20
Nondiabetic-minocycline (7) 364 ± 20
Diabetic-vehicle (9) 366 ± 19
Diabetic-minocycline (5) 365 ± 12Materials and methods
Reagents
All chemicals were obtained from Sigma-Aldrich (Poole, Dorset, UK)
unless otherwise stated.
Animal studies
All animal studies and procedures were licensed under the UK Ani-
mals (Scientiﬁc Procedures) Act 1986. Diabetes was induced in adult
male Wistar rats (250–325 g, Charles River, UK) with freshly dissolved
STZ (55 mg/kg in sterile saline, i.p.), administered following an over-
night fast. Diabetes was veriﬁed 3 days post-STZ (OptimumPlus;
MediSense, UK) and ratswith blood glucose N15 mmol/l were classiﬁed
as diabetic. STZ-diabetic and age-matched control rats weremaintained
for 4–12 weeks. For the minocycline-prevention study: rats were ran-
domly allocated into one of four treatment groups (control-vehicle
(n = 8); control-minocycline (n = 8); diabetic-vehicle (n = 10);
diabetic-minocycline (n = 10)). Minocycline was administered by
daily gavage rather than the intraperitoneal route to avoid deposition
of minocycline in the peritoneal cavity, which has been associated
with inﬂammatory lesions and variability in absorption (Fagan et al.,
2004). Treatment with minocycline 25 mg/kg, p.o or vehicle (water,
p.o.) commenced 3 days post-STZ, and continued daily for the duration
of the trial. Animals were monitored daily, weighed twice weekly and
maintained for 8 weeks post-STZ. Body weight and blood glucose data
are shown in Table 1.
An additional group of adult male Wistar rats (250–300 g) was daily
dosed with either minocycline (25 mg/kg p.o, n= 4) or vehicle (water,
p.o, n = 4) for 3 days. Rats were then anaesthetized with isoﬂurane
(2% in oxygen) and, under sterile conditions, the left sciatic nervewas ex-
posed at mid-thigh level. The sciatic nerve was crushed with the tips of
watchmaker's forceps (2 × 15 s) the wound was closed in layers and
the animals recovered under observation. Dosing continued daily for a
further 3 days, then rats were killed and ipsilateral and contralateral
lumbar (L)4/5 dorsal root ganglia (DRG) were removed for cell culture
and sciatic nerves removed for PCR 3 h post last dose of minocycline.
Nerve conduction velocity (NCV)
One day following the last dose of minocycline, rats were terminally
anaesthetized with isoﬂurane (2–4% in oxygen) and electromyograms
were recorded from plantar foot muscles on a Powerlab 4 with ABI
Scope software in response to stimulation (1.5–5 V, 2 ms pulses,ic control rats. Minocycline had no signiﬁcant effect on body weight or terminal blood glu-
ats from the diabetic-minocycline group became normoglycaemic between 4 and 8 weeks
pper limit of detection of glucosemeter, datawas assigned as 27.8 mmol/l. Data represents
ight (g) End body weight (g) End blood glucose (mmol/l)
471 ± 7 8.1 ± 1
370 ± 14⁎⁎⁎ 27.8 ± 0⁎⁎⁎
579 ± 18 9.1 ± 1
383 ± 10⁎⁎⁎ 27.8 ± 0⁎⁎⁎
612 ± 14 9.9 ± 1
396 ± 11⁎⁎⁎ 27.8 ± 0.0⁎⁎⁎
580 ± 39 5.3 ± 0.8
567 ± 63 6.8 ± 2.3
383 ± 50⁎⁎⁎ 27.7 ± 0.0⁎⁎⁎
431 ± 81⁎⁎⁎ 27.5 ± 0.2⁎⁎⁎
Table 2
Forward and reverse primer sequences. Primers were designed using Primer 3.0 and
Blast primer programmes, PPIB was used as a reference (house-keeping) gene.
Primer Forward primer sequence (5′-3′) Reverse primer sequence (5′-3′)
MMP2 ATGGCATTGCTCAGGATCCGT AGCCTTCTCTTCCTGTGGGG
MMP9 CTGCGTATTTCCATTCATCCTTCG CGAGTTGCCCCCAGTTACAG
Timp1 TGGGGTGTGCACAGTGTTTC CGCTCTGGTAGCCCTTCTCA
Timp2 CGGAAGGAGATGGCAAGATG CCATCCAGAGGCACTCATCC
Il-6 ATATGTTCTCAGGGAGTCTTG GTGCATCATCGCTGTTCATACA
TNF-α GCCACCACGCTCTTCTGT GGCAGCCTTGTCCCTTGA
PPIB GGAGATGGCAGGAGGA ACCACATCCATGCCTTCC
656 S. Ali et al. / Experimental Neurology 261 (2014) 654–665Powerlab 4) at the sciatic notch and Achilles tendon. The length of nerve
between the two stimulus points wasmeasured ex vivo. Motor NCVwas
calculated using the latencies of compound M waves, and sensory NCV
was calculated from H reﬂex latencies.
Tissue processing
Rats were killed by anaesthetic overdose and the L4/5 DRG, plantar
surface of hindpaws and sciatic nerveswere rapidly dissected and either
snap frozen on dry ice, or post-ﬁxed for 4 h in 4% paraformaldehyde (in
0.1 M phosphate buffer (PB)), cryoprotected (10–30% sucrose in
0.1 M PB at 4 °C over 48 h), frozen in OCT-embedding medium (VWR,
UK) and then stored at−80 °C.
Sensory neuron culture
Dissociated sensory neurons were prepared from DRG obtained
from either L4/5 DRG or all vertebral levels of adult male Wistar rats
(200–250 g, Charles River, UK). Sensory neurons were prepared as pre-
viously described (Gardiner et al., 2005). Neurons were then either
seeded onto repeatedly freeze-heated longitudinal sections of sciatic
nerve (Ferguson and Muir, 2000) obtained from control or diabetic
rats (8 week post-STZ) or onto laminin (2 μg/ml)-coated 8-well Lab-
Tek chamber slides (VWR, UK; (Gardiner et al., 2005)) and then treated
with combinations of: active MMP-2 (100–200 ng/ml); nerve growth
factor (NGF; 10 ng/ml); and minocycline (1–50 μM) for 18–48 h.
Media were removed for analysis using a commercial NGF ELISA kit
(NGD Emax Immunoassay G7330, Promega UK). Sensory neurons were
either lysed in ice-cold lysis buffer (0.5 M Tris, pH 7.6, 0.2 M NaCl,
10 mM CaCl2, 1% Triton-X-100), or ﬁxed with 2% paraformaldehyde
for 15 min at room temperature.
Gelatin zymography
Sciatic nerves were desheathed, homogenized in ice-cold lysis buffer
(0.5 M Tris, pH 7.6, 0.2 M NaCl, 10 mM CaCl2, 1% Triton-X-100), and cen-
trifuged (9000 g, 30min at 4 °C) and the supernatantwas collected. 20 μg
of protein from the supernatant was separated on SDS-polyacrylamide
gels (containing 4.13 mg/ml gelatin under non-reducing, non-
denaturing conditions). SDS was removed by incubating gels in wash
buffer (50 mM Tris–HCl, pH 7.6, 5 mM CaCl2, 1 μM ZnCl2, 2.5% Triton X-
100) to renature enzymes. Gels were incubated in reaction buffer (wash
buffer without detergent) for 72 h at 37 °C to stimulate gelatinolysis,
then stained with Coomassie Brilliant Blue R-250 (0.1% diluted in 40%
methanol and 10% acetic acid) for 1 h, then destained (in 10% methanol
and 1% acetic acid) until clear gelatinolytic bands appeared. Gels were
dried using DryEase Min-gel drying system (Invitrogen, UK), scanned
and semiquantitative densitometry was performed on raw digitized im-
ages using SigmaScan Pro5 software (SPSS, Chicago, IL). For visual clarity
within ﬁgures, the images were converted to greyscale and inverted
(Adobe Photoshop), so digested bands appear as black on a white
background.
Real-time PCR
Total RNA was extracted from sensory neuron cultures using an
RNeasy kit (Qiagen) and from desheathed sciatic nerve of control and
STZ-diabetic rats (4, 8 and12 weeks post-STZ) using theRNeasy Lipid Tis-
sueMini Kit (Qiagen). Genomic DNAwas removed using theDNA-free kit
(Ambion). Equal amounts of RNA were reverse transcribed using MMLV
reverse transcriptase (Applied Biosystems) and quantitative PCRwas car-
ried out using SYBR green (Applied Biosystems). Reactions were set up in
96 well plates and each sample was assayed in duplicate, with the inclu-
sion of a no template control (no cDNA) for each primer set. Plates were
cycled on an ABI 7300 real-time PCR machine: 55 °C for 5 min, followed
by 95 °C for 10 min, and 40 cycles of 95 °C for 15 s and 60 °C for 1 min.Data were normalized to cyclophilin B (PPIB). All primer pairs (see
Table 2) were optimised at a 60 °C annealing temperature using tradi-
tional PCR prior to use in a real-time PCR system.Immunohistochemistry and immunocytochemistry
Tissue sections were washed in PBS, and non-speciﬁc bindingwas
inhibited by incubation for 1 h in 5% normal donkey serum (in PBS
containing 0.2% Triton-X-100 (P-BST)). Transverse sciatic nerve sec-
tions (12 μm) were immunostained with a combination of anti-
MMP-2 (1:2000; Abcam, UK) and anti-S100β (1:500; Sigma, UK)
overnight at 4 °C. Slides were washed in PBS-T and incubated with
secondary antibodies (ﬂuorescein isothiocyanate (FITC)-conjugated
donkey anti-mouse and cyanine-3 (Cy-3)-conjugated donkey anti-
rabbit (1:500)) for 1 h at room temperature. Transverse sections of
hindpaw skin (20 μm) were immunostained overnight at 4 °C with
anti-PGP9.5 (1:4000; AbD Serotec). Slides were washed and incubat-
ed with secondary antibody (donkey anti-rabbit Cy3; 1:1000) for 1 h
at room temperature. Cultured sensory neurons were immuno-
stained overnight at 4 °C with anti-β (III)-tubulin (1:500; Sigma)
and with then donkey anti-mouse FITC (1:200). Following incuba-
tion in secondary antibodies (all from Jackson ImmunoResearch),
slides were washed and mounted in Vectashield containing DAPI
(Vector Labs, UK). Immunoﬂuorescence was visualised using a
Leica DMR ﬂuorescence microscope, Hamamatsu camera and soft-
ware or a Leica TCS SP5 AOB5 inverted confocal microscope using
100×/0.50 plan Flouotar objective and LASAF software.Image analysis
For analysis of neurite outgrowth, 20 randomly selected ﬁelds of view
perwell were used in order to calculate the percentage of neurite bearing
cells (deﬁned as neuronswith neurites longer than 1.5 times the associat-
ed cell body diameter). Then, images of every neurite-bearing neuron in
each Lab-Tek chamber, or on each individual sciatic nerve cryosection
were acquired to calculate the length of the longest neurite and neurite
density, using concentric ring analysis as previously described (Gardiner
et al., 2005) using SigmaScan software (SPSS, UK). Data represent
means ± standard deviation from independent culture experiments.
For analysis of intraepidermal nerve ﬁbre density, the number of
PGP-9.5-immunoreactive nerve ﬁbre proﬁles which crossed the der-
mis/epidermis border was counted from 5 randomly selected ﬁelds of
view from at least 5 sections per animal. Fibres that branched within
the epidermis were counted as a single IENF. The length of the epider-
mis was measured using SigmaScan software (SPSS, UK) and data are
expressed as mean density of IENF per unit length of epidermis (IENF/
mm) ± standard deviation (Lauria et al., 2005).
Animals, tissues and cells were all analysed in a blinded fashion to
prevent observer bias. Statistical analysiswas conducted using GraphPad
Prism 4.0 software using t-tests or one- or two-way ANOVA followed by
Bonferroni's Multiple Comparison Tests as appropriate for the data set.
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Active MMP-2 is constitutively present in the sciatic nerve and is
downregulated in diabetes
MMP-2-immunoreactivity was detected in both axons (asterisk,
Fig. 1A) and Schwann cells (arrows, Fig. 1A) in the sciatic nerve of con-
trol rats, with no detectable change in cellular localisation at 4, 8 or
12 weeks of diabetes (Fig. 1B shows 8 weeks post-STZ).
Gelatin zymography is a sensitive method used to measure levels
of both the latent proenzyme and the cleaved active enzyme (Platt
et al., 2003). Protease activity in sciatic nerve samples from bothA
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The functional consequence of this downregulation of active MMP-2
was investigated by seeding dissociated sensory neurons onto longitudi-
nal sections of sciatic nerve obtained from control or STZ-diabetic rats
(Fig. 2). Neurons plated onto control nerve substrata extended long
well-organisedneurites (Fig. 2A),whilst those plated on sciatic nerve sub-
strata from diabetic rats extended shorter neurites that were less closely-
associated with the Schwann cell basement membrane (Fig. 2B). Pre-
treatment of nerve sections from diabetic rats with active MMP-2
(10 μg/ml; 3 h) signiﬁcantly improved neurite extension (control:
199.5 ± 28 μm; diabetic: 129 ± 31 μm; diabetic pretreated with MMP-
2: 180± 28 μm, n=9–10 nerve sections from n=5 rats per condition).
In the absence of neurotrophic support, dissociated adult rat sensory
neurons remained largely quiescent (Figs. 3A, D). The addition of active
MMP-2 to neurons did not increase neuritogenesis (Fig. 3D) or alter cell
survival (data not shown) but did potentiate neurite outgrowth of
regenerating neurons (Figs. 3B–F). Neurons treated with MMP-2 ex-
tended signiﬁcantly longer (control: 75 ± 2 μm versus active MMP-2
(100 ng/ml): 139 ± 15 μm, Fig. 3E, p b 0.01) and more dense neurites
(Fig. 3F, p b 0.05). This facilitation of neurite outgrowth by the addition
of active MMP-2 was associated with a signiﬁcant increase in the levels
of NGF in the media (Fig. 5G, p b 0.05).
These data suggest that active MMP-2 can enhance neurite
outgrowth via remodelling of the ECM environment to one more
favourable for regeneration, and by increasing the release of NGF.
Minocycline treatment did not prevent large or small nerve ﬁbre deﬁcits in
experimental diabetes
The analgesic efﬁcacy ofminocycline in diabetes is well characterised;
therefore here we assessed the effects of minocycline on large and smallﬁbres and on the regulation of MMPs in peripheral nerve in diabetic and
age-matched control (nondiabetic) rats.
Minocycline treatment did not cause signiﬁcant changes in body
weight or terminal blood glucose levels in diabetic or nondiabetic rats
compared to vehicle-treated rats (Table 1). Vehicle-treated diabetic
rats developed signiﬁcant motor (Fig. 4A) and sensory (Fig. 4B) nerve
conduction velocity (NCV) deﬁcits compared to nondiabetic rats
(p b 0.001). Treatment with minocycline did not signiﬁcantly alter
motor or sensory NCV.
Therewas a signiﬁcant reduction in IENF in the plantar surface of the
hindpaw of diabetic rats compared to nondiabetic rats (Figs. 4C, E, G;
p b 0.001) and minocycline-treatment did not ameliorate this loss
(Figs. 4F, G). Interestingly, nondiabetic rats treated with minocycline
showed IENF deﬁcits compared to vehicle-treated nondiabetics
(Figs. 4C, D, G; p b 0.05). Taken together these data suggest that daily
minocycline does not afford signiﬁcant protection against peripheral
nerve dysfunction observed in experimental DPN and may negatively
impact on cutaneous innervation.Minocycline reduces neurite outgrowth from sensory neurons
The potential deleterious effects of minocycline on sensory neuron
growth were investigated by the direct addition of increasing doses of
minocycline to NGF-stimulated sensory neurons. Minocycline caused a
reduction in NGF-mediated (Figs. 5A–D) neurite initiation (Fig. 5E.
p b 0.05), elongation (Fig. 5F) and density (Fig. 5G). Neurite extension
was attenuated with as little as 1 μM of minocycline (Fig. 5F, NGF
alone: 222.5 ± 31 μm; 1 μM minocycline plus NGF: 186 ± 24 μm;
p b 0.05). This reduction of neurite outgrowth coincided with a signiﬁ-
cant reduction in levels of MMP-2 mRNA in sensory neurons treated
with minocycline (Fig. 5H, p b 0.05).
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Fig. 3.ActiveMMP-2potentiates neurite outgrowth from adult rat sensory neurons. In the absence of neurotrophic support dissociated sensory neurons remained largely quiescent (A, D).
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**p b 0.01; ***p b 0.005) one-way (D–E) or two-way (F) ANOVA followed by Bonferroni's Multiple Comparison Tests or t-test compared to control (G). Scale bar = 100 μm.
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could affect the regenerative capacity of sensory neurons following a
nerve crush injury. Injury responses, (MMP-2/-9, TIMP-1/-2, tumour
necrosis factor α (TNFα) and interleukin (IL)-6)) in the sciatic nerve
were measured using quantitative RT-PCR (Supp Fig. 1). We showed
that vehicle- and minocycline-treated control rats had identical injury
responses in the sciatic nerve. Nevertheless, preconditioning regenera-
tive responses of sensory neurons were attenuated in minocycline-
treated controls (Fig. 6). From vehicle-treated controls, there was very
little neurite outgrowth from the contralateral (non-injured) neurons
(Fig. 6A) whilst ipsilateral (preinjured) neurons extended numerous
elongated neurites (Fig. 6B). This preconditioning injury-enhanced
neurite outgrowth was attenuated in minocycline-treated controls
(Figs. 6C, D) with a signiﬁcant reduction in neurite initiation (Fig. 6E, ip-
silateral: minocycline-treated: 20 ± 8%; vehicle-treated: 32 ± 4.6%
neurite-bearing cells, p b 0.05). Whilst the overall mean length of the
longest neurite was not signiﬁcantly different between groups
(Fig. 6F), analysis of neurite length distribution showed that a greater
number of neurons from minocycline-treated controls extended signif-
icantly shorter neurites (Fig. 6G, ipsilateral: minocycline-treated:
34.8 ± 11.7% neurons extended neurites b150 μm compared withvehicle-treated: 19.2± 9.9%, p b 0.001). These data highlight a negative
impact of minocycline on sensory neurite outgrowth.Minocycline inhibits MMP-2 activity and mRNA expression in sciatic nerve
Since attenuation of neurite outgrowth by minocycline in vitro was
associated with downregulation ofMMP-2mRNA, we examined the ac-
tivity and expression of MMP-2 and TIMP-1/2 in sciatic nerve from dia-
betic and nondiabetic rats treated with either vehicle or minocycline.
By zymography we conﬁrmed active MMP-2 levels were again re-
duced in sciatic nerves from vehicle-treated diabetic compared to
vehicle-treated nondiabetic rats (Figs. 7A, B (ii), p b 0.0001).Minocycline
treatment of diabetic rats did not further affect the reduced levels of sci-
atic nerve MMP-2 (Fig. 7B (ii)). However, minocycline treatment of non-
diabetics reduced levels of both the pro and active MMP-2 compared to
vehicle-treated nondiabetics (Figs. 7A, B (i, ii), p b 0.0001). By RT-PCR
we show the expression of MMP-2 was signiﬁcantly reduced in nerves
from diabetic rats (Fig. 7C (i), p b 0.0001) and in minocycline-treated
nondiabetics compared with vehicle-treated nondiabetics (Fig. 7C (i),
p b 0.05). Minocycline treatment of diabetic rats was associated with a
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660 S. Ali et al. / Experimental Neurology 261 (2014) 654–665signiﬁcant increase in the expressionof TIMP-1 (Fig. 7C (ii) pb 0.05)with
no change in TIMP-2 mRNA (Fig. 7C (iii)).
These data suggest that in diabetes MMP-2 is downregulated at the
level of transcription and by reduced cleavage of the pro-form to the ac-
tive form and/or interactions of the active form with TIMPs. In nondia-
betic rats minocycline modulates MMP-2 by direct enzymatic
inhibition and transcriptional alterations in both MMP-2 and TIMP-1
mRNA.Discussion
In summary, we conﬁrmed that MMP-2 but not MMP-9 was consti-
tutively expressed in both pro and active forms in the adult rat sciatic
nerve (Ferguson and Muir, 2000; Shubayev and Myers, 2000). The ex-
pression and activity of MMP-2 (mRNA and protein) were downregu-
lated by either treatment with minocycline (an inhibitor of MMPs)
and/or induction of diabetes. The functional consequences of this
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661S. Ali et al. / Experimental Neurology 261 (2014) 654–665downregulation were a small but statistically signiﬁcant reduction in
IENF density in minocycline-treated nondiabetic rats, and in diabetes
the sciatic nerve was less supportive of sensory neuron growth. The
inhibitory effects of minocycline on regeneration were further demon-
strated by impaired preconditioning-injury-induced neurite outgrowth,
and its direct addition to sensory neurons impaired NGF-mediated
neurite outgrowth. In contrast, pretreatment of sciatic nerve substrata
from diabetic rats with active MMP-2 or the direct addition of active
MMP-2 to sensory neuron cultures promoted neurite elongation,potentially by increasing ECM turnover and/or increasing the local re-
lease of neurotrophins.
We examined the expression and activity of MMPs in the sciatic
nerve over a 12-week timecourse of diabetes and founddownregulation
of bothMMP-2mRNA and levels of activeMMP-2 in sciatic nerve. In ad-
dition we found no constitutive or diabetes-associated expression of
MMP-9, but conﬁrmed MMP-9 upregulation following nerve injury
(Platt et al., 2003). Our results differ from those reported by (Bhatt
and Veeranjaneyulu, 2010) who showed increased levels of both
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662 S. Ali et al. / Experimental Neurology 261 (2014) 654–665MMP-2 and MMP-9 in sciatic nerve 6 weeks post STZ injection. Whilst
we did not study this timepoint, we propose that an early transient in-
crease in MMPs may reﬂect initial attempts of nerve regeneration and
the inability to maintain increased activity of MMP-2/-9 from 8 weeks
onwards may explain the delays in Wallerian degeneration and failure
of nerve regeneration in diabetes (Kennedy and Zochodne, 2005). In di-
abetes the increased formation of advanced glycation residues (AGEs)
and altered properties of glycated ECM molecules produce similar
downregulation of MMP expression in other tissues; including MMP-7
in mesangial cells in diabetic nephropathy (McLennan et al., 2007)
and downregulation of MMP-1/-2 in dermal ﬁbroblasts (Rittie et al.,
1999). We have previously shown that AGE residues are increased in
ECM of sciatic nerve from STZ-diabetic rats (Duran-Jimenez et al.,
2009) and suggest that in addition to compromising protein function
through crosslinking they may also negatively regulate MMP-2 expres-
sion and activity.
We have shown that sciatic nerve substrata prepared from diabetic
rats were less supportive of sensory neuron growth. Pretreatment of
nerveswith activeMMP-2 rescued neurite elongation to levels observed
on nondiabetic rat nerve substrata, suggesting that reduced levels of
MMP-2 togetherwith increased levels of AGEsmay contribute to the ac-
cumulation of collagen and ECMmolecules in peripheral nerve (Bradley
et al., 2000; Giannini and Dyck, 1995; Hill and Williams, 2004; King
et al., 1989). Furthermore the addition of active MMP-2 enhanced
neurite outgrowth from dissociated adult sensory neurones, potentially
through increased release of NGF. In diabetic retinopathy altered ex-
pression and activity of MMP-7 has been shown to impair the homeo-
static balance between the pro-form and cleaved active form of NGF
and contribute to neurovascular dysfunction (Ali et al., 2011). Since
NGF deﬁcits have been described in diabetic neuropathy (Anand et al.,
1996; Hellweg and Hartung, 1990) we propose that reduced MMP-2
levels may directly alter the availability of active neurotrophins in dia-
betes. Collectively our data illustrates that reduced levels of active
MMP-2 (and absence of MMP-9) may contribute to a number of the
phenotypic dysfunctions observed in DPN.
Attempts to treat DPN can be divided into those directed at modiﬁ-
cation of the underlying disease process and those directed at symptom
suppression. The analgesic potential of minocycline has been described
in experimental models of chemotherapy-induced polyneuropathy(CIPN; (Boyette-Davis and Dougherty, 2011; Boyette-Davis et al.,
2011), DPN (Bhatt and Veeranjaneyulu, 2010; Morgado et al., 2011;
Pabreja et al., 2011; Zychowska et al., 2013) and nerve injury (Mika
et al., 2007). In these studies minocycline was administered at a wide
range of doses (100 μg–100 mg/kg) by a number of routes including in-
traperitoneal, intrathecal and gavage. Minocycline inhibits several en-
zymes acting within the apoptosis- and inﬂammatory-pathways
(MMP-2/-9, iNOS and COX), inhibits microglial cell activation, alters
the expression of inﬂammatory cytokines, scavenges reactive oxygen
species and alters potassium-chloride cotransporter-2 in the spinal
cord.
We administered minocycline orally at a dose of 25 mg/kg a route
and dose regimen which has previously been shown to cross the
blood brain barrier (Colovic and Caccia, 2003) and protect against
IENF loss in CIPN (Boyette-Davis and Dougherty, 2011; Boyette-Davis
et al., 2011). Following 8 weeks of daily minocycline-treatment we ob-
served reduced levels of both pro and active MMP-2 protein andmRNA
in sciatic nerve from nondiabetic-treated rats. In diabetic rats the al-
ready reduced levels of active MMP-2 in sciatic nerve were not further
impacted on by minocycline treatment. Interestingly nerves from
minocycline-treated diabetic rats showed upregulation of TIMP-1
mRNA, possibly indicating an altered pharmacokinetic proﬁle and al-
teredMMP/TIMP regulation between nondiabetic and diabetic rats. Ad-
ministration of minocycline at a higher dose (50 mg/kg, p.o) however
has been shown to reduce MMP-2/-9 levels in sciatic nerve of diabetic
rats (6 weeks post STZ (Bhatt and Veeranjaneyulu, 2010)) and follow-
ing peripheral nerve injury (Keilhoff et al., 2007). In our study
minocycline did not afford signiﬁcant protection against large (NCV)
and small ﬁbre (IENF) deﬁcits in DPN. NCV measurements were made
one day following the last dose of minocycline, therefore it is possible
that any transient protective effects ofminocycline onNCVwere not de-
tected. Surprisingly, treatment of nondiabetic rats was associatedwith a
small, but statistically signiﬁcant, reduction in IENF density. The nega-
tive effects of minocycline on sensory nerve regeneration were further
demonstrated by the ability of in vivo treatment of control rats to atten-
uate the preconditioning injury response of dissociated DRG following a
crush injury, and in vitro treatment to directly inhibit NGF-mediated
neurite outgrowth. This reduction in growth was associated with re-
duced expression of MMP-2 mRNA.
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Fig. 7. Levels of active MMP-2 decrease in the sciatic nerve with diabetes and minocycline-treatment. Age-matched nondiabetic and STZ-diabetic rats were treated with minocycline
(25 mg/kg p.o.) daily from 3 days post-STZ for 8 weeks. Proteolytic activity of MMP-2 and MMP-9 were assayed using gelatin zymography, each lane contained sciatic nerve protein
from an individual animal (n = 5 per group; std: MMP-9 and MMP-2 protein standard to act as positive control/marker). Bands corresponding in molecular weight to the pro- and
active-cleaved forms of MMP-2 were detected (A). Densitometric analysis (B i, ii) revealed a diabetes-associated decrease in active MMP-2 which was not altered by minocycline.
However,minocycline treatment of nondiabetic rats reduced both pro and activeMMP-2 (A, B i,ii). Quantitative RT-PCR analysis (C i–iii) revealed reducedMMP-2mRNAwithminocycline
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represent mean + s.d (*p b 0.05; ****p b 0.0001, two-way ANOVA followed by Bonferroni's Multiple Comparison Tests).
663S. Ali et al. / Experimental Neurology 261 (2014) 654–665Our studies add to the increasing evidence demonstrating the vari-
able and even detrimental effects exerted by minocycline on neuronal
and glial cells in a number of neurological diseases. For example,
minocycline did not improve functional outcome or regeneration fol-
lowing a rat spinal contusion injury (Diguet et al., 2004; Lee et al.,
2003) and worsened patient outcome in a clinical trial for amyotrophic
lateral sclerosis (Gordon et al., 2007). In organotypic rat spinal cord cul-
tures, high doses of minocycline were deleterious to motor neuron sur-
vival and impaired activation, survival and migration of microglia and
astrocytes (Pinkernelle et al., 2013). Minocycline treatment, in a sciatic
nerve transection/immediate graft repair injury model, showed im-
paired axonal regeneration, associated with reduced macrophage re-
cruitment and activation, retarded Wallerian degeneration and
reduced levels of MMP-2/9 and iNOS in the nerve graft (Keilhoff et al.,
2007). Importantly a few clinical case reports have describedneuropathy as an adverse event of minocycline treatment (ulnar neu-
ropathy, carpel tunnel syndrome, vasculitic neuropathy, axonal neurop-
athy) (Lawson et al., 2001; Thaisetthawatkul et al., 2011;Morgado et al.,
2011; Palamaras et al., 2008).
We hypothesise that the beneﬁcial versus detrimental effects of
minocycline treatment depend on the balance of targets that it interacts
with. In the absence of pathology, minocycline inhibits the constitutive
activity of MMPs in sciatic nerve which is essential for themaintenance
of nerve health and regeneration. In disease, alterations in levels of
MMPs, inﬂammation, oxidative stress and apoptosis means there is po-
tentially a wider range of targets for minocycline to interact with. The
exact contributions of these to the disease pathology and also timing
of treatment will determine therapy outcomes with minocycline. Fur-
ther experiments using minocycline in DPN, especially at the higher
doses (40–80 mg/kg) used to alleviate hyperalgesia or allodynia
664 S. Ali et al. / Experimental Neurology 261 (2014) 654–665(Bhatt and Veeranjaneyulu, 2010; Morgado et al., 2011; Pabreja et al.,
2011), are required to characterise any negative impact of minocycline
on IENF density.
Conclusion
We show that levels of active MMP-2 are downregulated in
peripheral nerve during diabetes and with treatment with minocycline.
We suggest that loss of MMP-2 is associated with ECM abnormalities
and reduced neurotrophin availability, which contributes to nerve
degeneration and IENF loss. Thus we propose that strategies to activate
MMP-2 may improve the regenerative capacity of peripheral nerve in
diabetes. Whilst our studies do not exclude the possible beneﬁcial
effects of minocycline in painful DPN, the present study does question
its long-termuse in a syndromewhere there is ongoingnerve pathology
and nerve regeneration is necessary to preserve or restore nerve
function.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.expneurol.2014.08.017.
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